New diabetes drug enters early safety testing
NCT ID NCT06945406
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called LY4057996 in 124 healthy volunteers and people with type 1 or type 2 diabetes. The main goal is to see if the drug is safe and what side effects it may cause. Participants receive the drug as a shot under the skin or into a vein, and blood tests measure how the body processes it. The study lasts 4 to 11 weeks, depending on the group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Profil Institut für Stoffwechselforschung
RECRUITINGNeuss, 41460, Germany
Contact Phone: •••-•••-••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Kidney clues may predict eye swelling after cataract surgery in diabetes patients
- Which medical adhesive stays put longest without itching? a head-to-head test in healthy women.
- AI-Powered trial asks: does adding a second drug cut heart failure risk?
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- New eye drop aims to tame ocular pain in early trial